Mayne Financial Statements From 2010 to 2024
| MAYNF Stock | USD 3.10 0.10 3.33% |
Check Mayne Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mayne Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Mayne financial statements analysis is a perfect complement when working with Mayne Pharma Valuation or Volatility modules.
Mayne |
Mayne Pharma Group Company Return On Asset Analysis
Mayne Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mayne Pharma Return On Asset | -0.0328 |
Most of Mayne Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mayne Pharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Mayne Pharma Group has a Return On Asset of -0.0328. This is 99.63% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—General industry. The return on asset for all United States stocks is 76.57% lower than that of the firm.
Mayne Pharma Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mayne Pharma's current stock value. Our valuation model uses many indicators to compare Mayne Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mayne Pharma competition to find correlations between indicators driving Mayne Pharma's intrinsic value. More Info.Mayne Pharma Group is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mayne Pharma's earnings, one of the primary drivers of an investment's value.About Mayne Pharma Financial Statements
Mayne Pharma stakeholders use historical fundamental indicators, such as Mayne Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Mayne Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Mayne Pharma's assets and liabilities are reflected in the revenues and expenses on Mayne Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Mayne Pharma Group. Please read more on our technical analysis and fundamental analysis pages.
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. Mayne Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Mayne Pink Sheet
Mayne Pharma financial ratios help investors to determine whether Mayne Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mayne with respect to the benefits of owning Mayne Pharma security.